

Paolo A Cortesi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/115509/publications.pdf>

Version: 2024-02-01

88
papers

35,551
citations

172457

29
h-index

53230

85
g-index

88
all docs

88
docs citations

88
times ranked

54706
citing authors

#	ARTICLE	IF	CITATIONS
1	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1789-1858.	13.7	8,569
2	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1211-1259.	13.7	5,578
3	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1736-1788.	13.7	4,989
4	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1923-1994.	13.7	3,269
5	Global, regional, and national burden of neurological disorders, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Neurology, The</i> , 2019, 18, 459-480.	10.2	2,625
6	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	13.7	2,123
7	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1345-1422.	13.7	1,879
8	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2017, 390, 1260-1344.	13.7	1,589
9	The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 245-266.	8.1	823
10	Global, regional, and national age-sex-specific mortality and life expectancy, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1684-1735.	13.7	716
11	Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 391, 2236-2271.	13.7	638
12	Global, regional, and national burden of congenital heart disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>The Lancet Child and Adolescent Health</i> , 2020, 4, 185-200.	5.6	338
13	Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study. <i>Journal of Hepatology</i> , 2016, 65, 524-531.	3.7	298
14	Population and fertility by age and sex for 195 countries and territories, 1950â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1995-2051.	13.7	294
15	Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors. <i>New England Journal of Medicine</i> , 2011, 365, 1684-1692.	27.0	209
16	Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. <i>Journal of Hepatology</i> , 2018, 69, 810-817.	3.7	199
17	Protective Role of Tacrolimus, Deleterious Role of Age and Comorbidities in Liver Transplant Recipients With Covid-19: Results From the ELITA/ELTR Multi-center European Study. <i>Gastroenterology</i> , 2021, 160, 1151-1163.e3.	1.3	130
18	Italian Population-Based Values of EQ-5D Health States. <i>Value in Health</i> , 2013, 16, 814-822.	0.3	122

#	ARTICLE	IF	CITATIONS
19	Liver transplantation for patients with acute-on-chronic liver failure (ACLF) in Europe: Results of the ELITA/EF-CLIF collaborative study (ECLIS). <i>Journal of Hepatology</i> , 2021, 75, 610-622.	3.7	96
20	Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the ProFEIBA study. <i>Haemophilia</i> , 2013, 19, 736-743.	2.1	59
21	Systematic literature review on economic implications and pharmaco-economic issues of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S72-84.	0.8	55
22	Delisting HCV-infected liver transplant candidates who improved after viral eradication: Outcome 2 years after delisting. <i>Liver International</i> , 2018, 38, 2170-2177.	3.9	54
23	Italy's health performance, 1990–2017: findings from the Global Burden of Disease Study 2017. <i>Lancet Public Health</i> , 2019, 4, e645-e657.	10.0	54
24	Cost-Effectiveness and Budget Impact of Emicizumab Prophylaxis in Haemophilia A Patients with Inhibitors. <i>Thrombosis and Haemostasis</i> , 2020, 120, 216-228.	3.4	48
25	Cost and Cost Effectiveness of Treatments for Psoriatic Arthritis: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2018, 36, 567-589.	3.3	39
26	Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). <i>Haemophilia</i> , 2016, 22, 96-102.	2.1	37
27	The socioeconomic burden of patients affected by hemophilia with inhibitors. <i>European Journal of Haematology</i> , 2018, 101, 435-456.	2.2	37
28	Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. <i>Contact Dermatitis</i> , 2014, 70, 158-168.	1.4	34
29	Trends in cardiovascular diseases burden and vascular risk factors in Italy: The Global Burden of Disease study 1990–2017. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 385-396.	1.8	34
30	COVID-19 in liver transplant candidates: pretransplant and post-transplant outcomes - an ELITA/ELTR multicentre cohort study. <i>Gut</i> , 2021, 70, 1914-1924.	12.1	30
31	A systematic literature review of the economic impact of ankylosing spondylitis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S136-41.	0.8	30
32	Epidemiologic and Economic Burden Attributable to First Spinal Fusion Surgery. <i>Spine</i> , 2017, 42, 1398-1404.	2.0	27
33	2020 position statement and recommendations of the European Liver and Intestine Transplantation Association (ELITA): management of hepatitis B virus-related infection before and after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 583-605.	3.7	27
34	The optimal timing of hepatitis C therapy in liver transplant-eligible patients: Cost-effectiveness analysis of new opportunities. <i>Journal of Viral Hepatitis</i> , 2018, 25, 791-801.	2.0	26
35	Costs and effectiveness of influenza vaccination: a systematic review. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2018, 54, 49-57.	0.4	22
36	Cost-effectiveness analysis of pharmacokinetic-driven prophylaxis vs. standard prophylaxis in patients with severe haemophilia A. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 425-430.	1.0	21

#	ARTICLE	IF	CITATIONS
37	Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products. <i>Blood Coagulation and Fibrinolysis</i> , 2017, 28, 627-637.	1.0	20
38	Cost-Utility Analysis of Bariatric Surgery in Italy: Results of Decision-Analytic Modelling. <i>Obesity Facts</i> , 2017, 10, 261-272.	3.4	20
39	Systematic literature review on economic implications and pharmacoeconomic issues of psoriatic arthritis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S126-31.	0.8	20
40	Compliance, persistence, costs and quality of life in young patients treated with antipsychotic drugs: results from the COMETA study. <i>BMC Psychiatry</i> , 2013, 13, 98.	2.6	19
41	Health economic models in hemophilia A and utility assumptions from a clinician's perspective. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1826-1831.	1.5	19
42	Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. <i>American Journal of Transplantation</i> , 2015, 15, 1817-1826.	4.7	19
43	Management of treatment-naïve chronic hepatitis C genotype 1 patients: a cost-effectiveness analysis of treatment options. <i>Journal of Viral Hepatitis</i> , 2015, 22, 175-183.	2.0	19
44	Direct-acting antivirals combination for elderly patients with chronic hepatitis C: A cost-effectiveness analysis. <i>Liver International</i> , 2017, 37, 982-994.	3.9	19
45	Benefits in pain perception, ability function and health-related quality of life in patients with failed back surgery syndrome undergoing spinal cord stimulation in a clinical practice setting. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 68.	2.4	16
46	Location and allocation: Inequity of access to liver transplantation for patients with severe acute-on-chronic liver failure in Europe. <i>Liver Transplantation</i> , 2022, 28, 1429-1440.	2.4	16
47	Clinical epidemiology of hand eczema in patients accessing dermatological reference centres: results from Italy. <i>British Journal of Dermatology</i> , 2015, 172, 187-195.	1.5	15
48	Patients', physicians', nurses', and pharmacists' preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. <i>Patient Preference and Adherence</i> , 2018, Volume 12, 2153-2168.	1.8	15
49	Health related quality of life in chronic liver diseases. <i>Liver International</i> , 2020, 40, 2630-2642.	3.9	15
50	Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A. <i>Haemophilia</i> , 2021, 27, e422-e433.	2.1	14
51	Modern Treatments of Haemophilia: Review of Cost-Effectiveness Analyses and Future Directions. <i>Pharmacoeconomics</i> , 2018, 36, 263-284.	3.3	13
52	Systematic review: economic evaluations of HCV screening in the direct-acting antivirals era. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1126-1133.	3.7	13
53	The rationale of pharmacoeconomic analysis in rheumatologic indications. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S64-71.	0.8	11
54	Effective but costly: How to tackle difficult trade-offs in evaluating health improving technologies in liver diseases. <i>Hepatology</i> , 2016, 64, 1331-1342.	7.3	10

#	ARTICLE	IF	CITATIONS
55	Sacubitril/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context. <i>European Journal of Heart Failure</i> , 2017, 19, 1551-1553.	7.1	10
56	Thromboembolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. <i>Blood Advances</i> , 2017, 1, 2637-2642.	5.2	9
57	Feasibility, acceptability and construct validity of EQ-5D in systemic sclerosis. <i>Swiss Medical Weekly</i> , 2016, 146, w14394.	1.6	9
58	Antidepressants Drug Use during COVID-19 Waves in the Tuscan General Population: An Interrupted Time-Series Analysis. <i>Journal of Personalized Medicine</i> , 2022, 12, 178.	2.5	8
59	Impact of COVID-19 Lockdown, during the Two Waves, on Drug Use and Emergency Department Access in People with Epilepsy: An Interrupted Time-Series Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 13253.	2.6	8
60	The economic impact of hypercholesterolemia and mixed dyslipidemia: A systematic review of cost of illness studies. <i>PLoS ONE</i> , 2021, 16, e0254631.	2.5	7
61	Cost-minimization analysis of a wearable cardioverter defibrillator in adult patients undergoing <scp>ICD</scp> explant procedures: Clinical and economic implications. <i>Clinical Cardiology</i> , 2021, 44, 1497-1505.	1.8	7
62	Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 68-75.	0.8	7
63	Costs and effects of cardiovascular risk reclassification using the ankle-brachial index (ABI) in addition to the Framingham risk scoring in women. <i>Atherosclerosis</i> , 2021, 317, 59-66.	0.8	6
64	Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. <i>PLoS ONE</i> , 2017, 12, e0179523.	2.5	6
65	The value of wearable cardioverter defibrillator in adult patients with recent myocardial infarction: Economic and clinical implications from a health technology assessment perspective. <i>International Journal of Cardiology</i> , 2022, 356, 12-18.	1.7	6
66	Clinical outcome indicators in chronic hepatitis B and C: A primer for value-based medicine in hepatology. <i>Liver International</i> , 2020, 40, 60-73.	3.9	5
67	Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. <i>Clinical Drug Investigation</i> , 2020, 40, 319-326.	2.2	5
68	Cost-Effectiveness Analysis of Rivaroxaban Plus Aspirin Compared with Aspirin Alone in Patients with Coronary and Peripheral Artery Diseases in Italy. <i>Clinical Drug Investigation</i> , 2021, 41, 459-468.	2.2	5
69	Joint Disease and the Potential for Improved Joint Health in Inhibitor Patients Who Have a Good Response to aPCC Prophylaxis: Data From the Profeiba Study. <i>Blood</i> , 2012, 120, 3374-3374.	1.4	5
70	Haemophilia management and treatment: An Italian survey on patients'™, caregivers'™ and clinicians'™ point of view. <i>Haemophilia</i> , 2022, 28, 254-263.	2.1	5
71	Use of Health-Related Quality-of-Life Measurements to Estimate Individuals'™ Health on Screening. <i>Acta Chirurgica Belgica</i> , 2013, 113, 406-414.	0.4	3
72	Cost-Utility Analysis of Biologic Therapies to Treat Chronic Plaque Psoriasis in Italy: The Importance of Using Updated and Adequate Social Tariffs to Calculate Quality-Adjusted Life-Years. <i>BioDrugs</i> , 2015, 29, 69-69.	4.6	3

#	ARTICLE	IF	CITATIONS
73	Reply Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. <i>Drugs</i> , 2016, 76, 1063-1065.	10.9	3
74	Optimising the clinical strategy for autoimmune liver diseases: Principles of value-based medicine. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 1415-1422.	3.8	3
75	COVID-19 Outbreak Impact on Anticoagulants Utilization: An Interrupted Time-Series Analysis Using Health Care Administrative Databases. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1115-1118.	3.4	3
76	Meta-Analysis on Incidence of Inhibitors in 1,945 Previously Untreated Patients Treated with Recombinant Factor VIII Products: Is There a Difference?. <i>Blood</i> , 2015, 126, 289-289.	1.4	3
77	Cost-effectiveness analysis of new drugs for chronic hepatitis C: The importance of updating utility values. <i>Hepatology</i> , 2015, 61, 1096-1097.	7.3	2
78	[Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy]. <i>Farmeconomia E Percorsi Terapeutici</i> , 2016, 17, 67-80.	0.1	2
79	The Value and Sustainability of Ocrelizumab in Relapsing Multiple Sclerosis: A Cost-Effectiveness and Budget Impact Analysis. <i>Farmeconomia E Percorsi Terapeutici</i> , 2019, 20, .	0.1	2
80	Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. <i>PLoS ONE</i> , 2022, 17, e0264123.	2.5	2
81	Multiple Sclerosis Progressive Courses: A Clinical Cohort Long-Term Disability Progression Study. <i>Value in Health</i> , 2022, 25, 1489-1498.	0.3	2
82	About the Reliability of the Critical Review to Investigate the Generalizability of Economic Evaluations Conducted in Italy. <i>Value in Health</i> , 2016, 19, 697.	0.3	1
83	Use of health-related quality-of-life measurements to estimate individuals' health on screening. <i>Acta Chirurgica Belgica</i> , 2013, 113, 406-14.	0.4	1
84	Cost-effectiveness of the early arthritis clinic organizational model: the ELECTRA study. <i>Arthritis Care and Research</i> , 2022, , .	3.4	1
85	Real-World Clinical Outcomes and Replacement Factor VIII Consumption in Patients with Haemophilia A in Italy: A Comparison between Prophylaxis Pre and Post Octocog Alfa (BAY 81-8973). <i>Journal of Clinical Medicine</i> , 2022, 11, 3434.	2.4	1
86	Health Technology Assessment on the use of the Wearable Cardioverter Defibrillator in Patients with Myocardial Infarction and with ICD Explant. <i>Farmeconomia E Percorsi Terapeutici</i> , 2021, 22, .	0.1	0
87	Variability of treatment modalities and intensity in patients with severe haemophilia A on prophylaxis: Results from the Italian national registry. <i>European Journal of Haematology</i> , 2021, 107, 408-415.	2.2	0
88	Benefit and costs of surveillance on cancer risk patients: the example of pancreatic cystic tumors. <i>European Journal of Public Health</i> , 2020, 30, .	0.3	0